This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Pembrolizumab making it ideal for research use. This Pembrolizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 ａnd CD8 thymocytes as well as activated T ａnd B lymphocytes ａnd myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 ａnd PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, ａnd T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance ａnd prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, ａnd breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 ａnd its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Pembrolizumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.

BXC-SIM0010體內SIM人類PD-1抗體（帕博利珠單抗生物類似藥）：

這種非治療性生物仿制藥抗體使用與治療性抗體Pembrolizumab相同的可變區域，使其成為研究用途的理想選擇。這種Pembrolizumab生物仿制藥與人PD-1（程序性死亡-1）反應，也稱為CD279。PD-1是由Pdcd50基因編碼的55-1 kDa細胞表面受體，屬于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上短暫表達。PD-1在成功消除抗原后表達下降。

BioXCell艾美捷體內SIM人類PD-1抗體（帕博利珠單抗生物類似藥）規格：

#  BXC-SIM0010

Isotype Human IgG4

Recommended Isotype Control(s) RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme

Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer

Immunogen Human PD-1

Reported Applications Blocking of PD-1/PD-L signaling

Functional assays

Formulation PBS, pH 7.0

Contains no stabilizers or preservatives

Endotoxin <1EU/mg (<0.001EU/μg)

Determined by LAL gel clotting assay

Aggregation <5%

Determined by DLS

Purity >95%

Determined by SDS-PAGE

Sterility 0.2 μM filtered

Production Purified from cell culture supernatant

Purification Protein A

RRID AB_2894731

Molecular Weight 150 kDa

Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

同種型 人免疫球蛋白G4

推薦的同種型對照 RecombiMAb人IgG4（S228P）同種型對照，抗母蛋溶菌酶

推薦的稀釋緩沖液 體內純 pH 7.0 稀釋緩沖液

免疫原 人類PD-1

報告的應用程序 阻斷PD-1/PD-L信號傳導

功能檢測

配方 PBS，pH 7.0

不含穩定劑或防腐劑

內毒素 <1EU/mg （<0.001EU/μg）

通過LAL凝膠凝血測定法測定

集合體 <5%

由 DLS 確定

純度 >95%

由 SDS-PAGE 決定

無 菌 0.2 μM 過濾

生產 從細胞培養上清液中純化

純化 蛋白A

里德 AB_2894731

分子量 150 千達

鼠病原體檢測 外切粒菌/鼠痘病毒： 陰性 漢坦病毒： 陰性 K 病毒： 陰性乳酸脫氫酶升高病毒： 陰性 淋巴細胞性脈絡叢腦膜炎病毒： 陰性小鼠腺病毒： 陰性小鼠巨細胞病毒： 陰性小鼠肝炎病毒： 陰性小鼠分鐘病毒： 陰性小鼠諾如病毒： 陰性小鼠細小病毒： 陰性

小鼠輪狀病毒：肺支原體陰性：陰性 小鼠肺炎病毒：陰性 多瘤病毒：陰性呼腸孤病毒篩查：陰性 仙臺病毒：陰性 泰勒鼠腦脊髓炎：陰性

存儲 抗體溶液應以4°C的儲備濃度儲存。 不要凍結。

來源：https://www.amyjet.com/products/BXC-SIM0010-1mg.shtml